TNYA
Tenaya Therapeutics Inc
0.5803$
+6.6%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
Tenaya Therapeutics Inc (TNYA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -23 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.2 | -7.3 | -9.5 | -10 | -16 | -12 | -17 | -16 | -29 | -25 | -28 | -23 | -30 | -26 | -24 | -22 | -29 | -24 | -20 | -18 | -23 | -16 | -16 | -14 | -19 | -23 | -72 | |
| 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 1.1 | 0.8 | 1.0 | 1.3 | 2.1 | 2.1 | 2.1 | 2.2 | 2.2 | 2.2 | 2.2 | 2.1 | 2.1 | 2.1 | 2.7 | 2.4 | 1.9 | 1.8 | 1.8 | 3.5 | 8.9 | |
| 0.2 | 0.2 | 0.2 | 0.2 | 0.4 | 0.5 | 1.0 | 1.0 | 2.1 | 3.0 | 3.2 | 3.2 | 3.5 | 3.8 | 4.0 | 3.9 | 4.2 | 4.6 | 3.9 | 3.8 | 3.7 | 3.6 | 2.9 | 2.7 | 2.2 | 3.9 | 12 | |
| 0.2 | 0.2 | 0.0 | – | 0.6 | 0.8 | 1.3 | 1.6 | 2.1 | 3.0 | 3.7 | 3.4 | 3.6 | 4.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.6 | 0.1 | -0.9 | -4.0 | 1.7 | -0.4 | 7.5 | -1.2 | -1.9 | -2.7 | 5.0 | -4.4 | 0.7 | -1.2 | -0.7 | -3.6 | -1.9 | -1.3 | -1.0 | -3.4 | 1.0 | -0.9 | 0.9 | -4.6 | 8.2 | 3.6 | |
| 0.4 | 1.0 | 0.2 | 8.2 | 4.3 | 3.2 | 5.0 | 13 | 8.6 | 7.2 | 4.1 | 0.8 | 0.6 | 0.2 | 0.0 | 0.4 | 0.6 | 0.1 | 0.2 | 0.2 | 0.4 | 0.1 | 0.0 | 0.1 | 0.0 | 0.2 | 0.3 | |
| 2.3 | -1.0 | -0.2 | -8.2 | -4.3 | -3.2 | -168 | -63 | 16 | 30 | 31 | 6.0 | 8.1 | 25 | 30 | -15 | -4.5 | 22 | -30 | 14 | 22 | 25 | 8.9 | -0.1 | 0.0 | -0.2 | 8.6 | |
| – | – | 0.0 | 0.0 | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | 77 | -0.5 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 31 | 0.0 | 31 | 86 | 20 | -1.3 | 190 | 0.0 | 0.0 | 0.3 | 0.0 | 77 | -0.5 | 4.2 | 0.0 | 0.4 | 47 | 0.6 | 0.0 | 0.4 | 50 | -0.5 | 0.4 | 58 | -0.4 | 0.5 | 59 | |
| 25 | -8.3 | 21 | 67 | -0.1 | -17 | 5.2 | -79 | -12 | 5.0 | 3.5 | 61 | -23 | 3.0 | 6.9 | -36 | 14 | -1.4 | -50 | -3.9 | 49 | 8.9 | -6.4 | 44 | -20 | -22 | -4.2 | |
| -8.7 | -8.3 | -9.7 | -19 | -20 | -15 | -22 | -29 | -37 | -33 | -32 | -23 | -31 | -26 | -24 | -22 | -29 | -24 | -20 | -19 | -23 | -16 | -16 | -14 | -19 | -23 | -72 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.